And as ADRB3 was described to be the main receptor mediating adrenergic-stimulated lipolysis in rodent adipocytes (Bloom et al., 1992, Guerra et al., 1998, Himms-Hagen et al., 1994, Susulic et al., 1995, Xiao et al., 2015), direct sympathomimetic agents, such as the ADRB3 agonist CL-316,243, were once regarded as potential anti-obesity therapies. Here, ADRB3 is linked to obesity due to melanocortin 4 receptor deficiency.